Replimune (REPL) Times Interest Earned (2019 - 2026)
Replimune (REPL) posted Times Interest Earned of -$20.25 for Q1 2026, down 1072.72% sequentially from -$1.73 in Q4 2025, and down 102.96% YoY from $683.86 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Times Interest Earned (2019 - 2026) Analysis & Trends
Replimune has reported Times Interest Earned for 10 years, with the latest figure at -$20.25 in Q1 2026.
- Quarterly Times Interest Earned fell 102.96% year-over-year to -$20.25 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.35 (up 37.3% YoY) and the FY2026 annual result came in at -$1.03, up 13.15% from the prior year.
- Times Interest Earned eased to -$20.25 in Q1 2026 per REPL's latest filing, from -$1.73 in the prior quarter.
- Over five years, Times Interest Earned peaked at $683.86 in Q1 2025 and troughed at -$27.0 in Q1 2023.
- A 5-year average of $42.88 and a median of -$1.31 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned tumbled 120.42% in 2023, then surged 2964.36% in 2025.
- Over 5 years, Times Interest Earned stood at -$0.84 in 2022, then plunged by 43.37% to -$1.2 in 2023, then dropped by 23.86% to -$1.49 in 2024, then decreased by 16.13% to -$1.73 in 2025, then sank by 1072.72% to -$20.25 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$20.25, -$1.73, and -$1.99 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 1.42 |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.08 |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - | -26.44 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.44 |
| Mar 31, 2026 | -30.98 |
| Dec 31, 2025 | -49.02 |
| Sep 30, 2025 | -56.65 |
| Jun 30, 2025 | -61.30 |
| Mar 31, 2025 | -54.30 |
| Dec 31, 2024 | -45.53 |
| Sep 30, 2024 | -40.97 |
| Jun 30, 2024 | -40.23 |
| Mar 31, 2024 | -41.55 |
| Dec 31, 2023 | -55.87 |
| Sep 30, 2023 | -66.84 |
| Jun 30, 2023 | -49.91 |
| Mar 31, 2023 | -51.85 |
| Dec 31, 2022 | -44.24 |
| Mar 31, 2021 | -22,184.00 |
| Dec 31, 2020 | -82.09 |
| Sep 30, 2020 | -68.75 |
| Jun 30, 2020 | -62.79 |
| Mar 31, 2020 | 55.54 |